Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes

Fibroblast growth factor 21 (FGF21) is a promising drug candidate for the treatment of type 2 diabetes. However, the use of wild type native FGF21 is challenging due to several limitations. Among these are its short half-life, its susceptibility to in vivo proteolytic degradation and its propensity...

Descripción completa

Detalles Bibliográficos
Autores principales: Hecht, Randy, Li, Yue-Sheng, Sun, Jeonghoon, Belouski, Ed, Hall, Michael, Hager, Todd, Yie, Junming, Wang, Wei, Winters, Dwight, Smith, Stephen, Spahr, Chris, Tam, Lei-Ting, Shen, Zhongnan, Stanislaus, Shanaka, Chinookoswong, Narumol, Lau, Yvonne, Sickmier, Allen, Michaels, Mark Leo, Boone, Thomas, Véniant, Murielle M., Xu, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507880/
https://www.ncbi.nlm.nih.gov/pubmed/23209571
http://dx.doi.org/10.1371/journal.pone.0049345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507880/
https://www.ncbi.nlm.nih.gov/pubmed/23209571
http://dx.doi.org/10.1371/journal.pone.0049345

Ejemplares similares